RHP
Henan Runhong Pharmaceutical Co., Ltd. (河南润弘制药股份有限公司) is a Chinese integrated pharmaceutical manufacturer, one of China's largest small-volume injection producers, holding 240+ drug approvals spanning cardiovascular, TCM, and emergency-rescue products, and serving hospitals, pharmacies, and clinics nationally via direct sales and distributor networks including Jiuzhou Tong Group.
- Company typePrivate
- Founded1970
- HeadquartersXinzheng, China
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What RHP does
Henan Runhong Pharmaceutical Co., Ltd. (河南润弘制药股份有限公司, "RHP") is a Chinese integrated pharmaceutical manufacturer founded in 1970 and headquartered in Xinzheng City, Henan Province. The company holds over 240 drug approval numbers across chemical drugs, Chinese patent medicines, and big-health product categories, with therapeutic focus on cardiovascular and cerebrovascular disease and TCM analgesic products. It is widely recognized as one of China's largest small-volume injection manufacturers; its portfolio spans injections, capsules, tablets, and lotions, including the market-leading Vinpocetine Injection ("Runtan" brand, ~70% domestic share), Atropine Sulfate Injection (first-rank winner in China's 9th national volume-based procurement), Furosemide Injection (passed generic consistency evaluation), and a newly NMPA-approved Epinephrine Hydrochloride Injection for emergency rescue indications. The product mix is distributed across over 240 SKUs serving cardiovascular, pain management, anti-infective, and rescue indications.
RHP's production platform is centered on the Runhong Pharmaceutical Industrial Park — a 400-acre site in the Xinzheng New Port Industrial Cluster opened in November 2020 after approximately RMB 1 billion (~US$150M) of investment and comprising 11 modernized production lines covering small-volume injections, oral solid dosages, Chinese medicine decoction pieces, and freeze-dried powder injections. The technological foundation includes fully automated small-volume injection production systems, industrial AGV transport, automated high-rack warehouse storage, fully automated TCM extraction systems, online industrial wastewater monitoring, and a "code-based release" tracking system for end-point quality surveillance. Subsidiary structure spans Henan Runhong Bencao Pharmaceutical Co., Ltd. (TCM formulas and granules), Henan Runhong Pharmaceutical Sales Co., Ltd. (distribution), Henan Jingkang Pharmaceutical Co., Ltd. (API manufacturing, integrated via 2019 strategic cooperation), Henan Lixiang Enterprise Management Co., Ltd., and Hubei Jintaiyuan Biomedicine Co., Ltd. (biological medicines).
The revenue model is B2B drug manufacturing and sales. GTM combines a direct sales force with channel/distributor partnerships — most notably a recent strategic alliance with Jiuzhou Tong Group, which provides a national modernized logistics network and professional hospital pure-sales system. Pricing is materially shaped by China's national volume-based procurement (GPO) policy, with RHP bidding into multiple batches via consolidated tender and securing first-rank positions in key batches. End customers span public/private hospitals, retail pharmacies (chain and independent), and grassroots clinics across China. Marketing channels include national drug trade fairs (e.g., 药交会), academic exchange programs with healthcare institutions and universities, and mainstream media coverage via Xinhua, Henan Daily, and industry publications. RHP filed an A-share IPO tutoring record with CITIC Securities via the Henan Securities Regulatory Bureau in February 2019; the listing process has not yet resulted in a completed IPO as of the available data.
RHP firmographics
Firmographics- Name
- RHP
- Legal name
- 河南润弘制药股份有限公司
- Website
- https://runhong-pharm.com
- Company type
- Private
- Founded year
- 1970
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Henan Runhong Pharmaceutical Co., Ltd. (河南润弘制药股份有限公司) is a Chinese integrated pharmaceutical manufacturer, one of China's largest small-volume injection producers, holding 240+ drug approvals spanning cardiovascular, TCM, and emergency-rescue products, and serving hospitals, pharmacies, and clinics nationally via direct sales and distributor networks including Jiuzhou Tong Group.
- Ownership category
- akta.pro rank
RHP industry classification
Industry- Product category
- Pharmaceutical Manufacturing
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL)
- akta.pro secondary industry
- Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)
Keywords
Where RHP is headquartered
LocationHeadquarters
- HQ city
- Xinzheng
- HQ country
- China
- HQ region
- Asia
Offices3 records
Markets served
RHP business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales
Revenue model
- 药品生产与销售: 润弘制药主要通过研发、生产和销售药品获取收入，产品涵盖中成药、化学药、大健康等领域。拥有240余种药品批准文号，重点聚焦心脑血管类和中药疼痛类产品，业务覆盖全国大部分医院、药店和诊所。
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Transaction based/ take rate | Multi-year contract | 国家集中带量采购（国采） |
Go-to-market motion2 records
Distribution channels4 records
Marketing channels3 records
RHP product offering
Product offeringCore offering
Henan Runhong Pharmaceutical Co., Ltd. (RHP) is an integrated pharmaceutical manufacturer engaged in the R&D, production, and sale of small-volume injections, capsules, tablets, and lotions. The company holds over 240 drug approval numbers and focuses on cardiovascular drugs and traditional Chinese medicine (TCM) pain products. RHP produces generic formulations including Vinpocetine Injection, Nitroglycerin Injection, and Epinephrine Hydrochloride Injection.
Product overview
RHP (润弘制药, Henan Runhong Pharmaceutical Co., Ltd.) operates as an integrated pharmaceutical manufacturer offering a broad portfolio of chemical drugs and traditional Chinese medicines across multiple dosage forms. The company holds over 240 drug approval numbers covering cardiovascular, pain management, anti-infective, and other therapeutic areas. The product portfolio is organized into four main dosage form categories: small-volume injections (注射剂, representing the company's core strength with 11 production lines), capsules (胶囊剂), tablets (片剂), and lotions (洗剂). Key products include the market-leading Vinpocetine Injection (润坦, ~70% domestic market share), cardiovascular drugs such as Nitroglycerin Injection and Epinephrine Hydrochloride Injection, TCM products including Gandan Shukang Jiaonang and Chaihu Injection, and commonly used injectables such as Dexamethasone Sodium Phosphate Injection, Furosemide Injection (which passed generic consistency evaluation), and Atropine Sulfate Injection (first-ranked winner in the 9th national volume-based procurement). RHP's subsidiary Henan Runhong Bencao Pharmaceutical Co., Ltd. produces TCM formulas and granules, extending the portfolio into Chinese herbal medicine.
Differentiator
Problem solved
Functional benefit
Products and services
- Vinpocetine Injection (长春西汀注射液)
- Nitroglycerin Injection (硝酸甘油注射液)
Quantifiable outcome
- 小容量医用水针剂占全国市场份额约30%
- +2 more outcomes
Companies that use RHP
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles1 record
RHP technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
RHP partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered 核心, 重要 and 一般.
- 九州通集团核心九州通集团作为国内领先的医药分销企业，拥有覆盖全国的现代化医药物流网络和专业的医院纯销体系。双方围绕第十二批国家组织药品集中带量采购品种展开合作，并就中风回春片、归脾丸等中成药品种的市场推广与渠道合作达成重要共识。
- 创泰生物重要润弘制药与创泰生物举行战略合作签约仪式，双方将携手并进，共绘生物医药新篇章。
- 大道隆达一般润弘制药与大道隆达举行战略合作伙伴签约仪式，建立长期战略合作关系。
- 郑州大学重要润弘制药与郑州大学药学院举行校企合作签约暨授牌仪式，双方将在人才培养、科研合作等方面开展深入合作。郑州大学教务处副处长、药学院执行院长等出席仪式。
- 中关村亚太生命科技研究院核心双方就生命健康领域打造可持续发展战略规划合作举行签约仪式，围绕人才引进、技术转化、项目研发、共建生命科学园等项目展开合作，旨在生物医药领域进行全方位合作，把润弘制药工业园建成全国领先的小容量注射剂生产研发基地。
- 浪潮软件重要河南润弘制药与河南浪潮软件合作实施"集团管控型"ERP项目，打造企业信息化管理标杆工程，提升公司整体信息化水平。
- 浙江大学一般与浙江大学、哈尔滨工业大学等多所院校合作建设现代化生产线，开展技术研发合作。
- 哈尔滨工业大学一般与浙江大学、哈尔滨工业大学等多所院校合作建设现代化生产线，开展技术研发合作。
Scale indicators7 records
Recent moves9 records
Expansion highlights6 records
RHP competitors and assessment
Company assessmentBroad incumbents
- Shanghai Pharmaceuticals Holding (上海医药): One of China's largest integrated pharma groups spanning branded drugs, generics, TCM, and distribution. Comparable as a broad incumbent in cardiovascular and generic injectables, with substantially larger scale.
- Fosun Pharma (复星医药): Diversified Chinese pharma incumbent spanning innovative drugs, generics, biologics, and diagnostics. Comparable as a broad incumbent with overlapping cardiovascular and injection franchises.
- China Grand Pharmaceutical and Healthcare Holdings (远大医药): Hong Kong-listed Chinese pharma with broad cardiovascular, anti-infective, and emergency-care injectable portfolio. Overlapping product categories and similar channel exposure.
Others
- Jointown Pharmaceutical Group (九州通): Strategic distribution partner of RHP and one of China's largest pharmaceutical distributors. Included as a channel/ecosystem peer given its role in RHP's national channel strategy.
Direct peers
- Salubris Pharmaceuticals (信立泰): Chinese pharma with strong cardiovascular drug portfolio including Telmisartan (also produced by RHP) and similar VBP participation; comparable in therapeutic focus and channel dynamics.
- China Resources Double-Crane Pharmaceutical (华润双鹤): Major Chinese generic injectable drug manufacturer with similar focus on small-volume injections and core cardiovascular product portfolio. Directly comparable in production-line structure, VBP exposure, and channel mix.
- Sichuan Kelun Pharmaceutical (科伦药业): Leading Chinese injectable drug manufacturer with strong small-volume and large-volume injection manufacturing capabilities. Most direct peer on production technology and VBP-driven generic injectables.
- Livzon Pharmaceutical Group (丽珠集团): Diversified Chinese pharma combining chemical drug injections, TCM, and biochemicals. Comparable in product mix spanning small-volume injectables and TCM preparations.
- Humanwell Healthcare Group (人福医药): Chinese pharmaceutical manufacturer with overlapping therapeutic portfolios in cardiovascular, anti-infectives, and emergency-care injectables, plus similar generic-drug and channel structure.
Emerging players
- Jichuan Pharmaceutical (济川药业): Chinese pharma with notable TCM and chemical drug portfolio including pediatric and pain-management categories. Comparable in TCM/chemical drug blend, though with different dosage-form mix.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
RHP compliance and trust
Trust signalCompliance5 records
RHP financial estimates
Financial estimateRevenue estimate
Valuation estimate
RHP leadership team
Management profileNumber of profiles
Profiles2 records
RHP subsidiaries and ownership
Company hierarchySubsidiaries5 records
RHP funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
RHP M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about RHP
What does RHP do?
Henan Runhong Pharmaceutical Co., Ltd. (RHP) is an integrated pharmaceutical manufacturer engaged in the R&D, production, and sale of small-volume injections, capsules, tablets, and lotions. The company holds over 240 drug approval numbers and focuses on cardiovascular drugs and traditional Chinese medicine (TCM) pain products. RHP produces generic formulations including Vinpocetine Injection, Nitroglycerin Injection, and Epinephrine Hydrochloride Injection.
Is RHP a public or private company?
RHP is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was RHP founded?
RHP was founded in 1970. It employs 11 to 50 people.
Where is RHP based?
RHP is headquartered in Xinzheng, China, in the Asia region.
How does RHP make money?
One revenue line is on record: 药品生产与销售.
Who are RHP's main competitors?
Broad incumbents on record are Shanghai Pharmaceuticals Holding (上海医药), Fosun Pharma (复星医药) and China Grand Pharmaceutical and Healthcare Holdings (远大医药). Jointown Pharmaceutical Group (九州通) is listed as an others. Direct peers are Salubris Pharmaceuticals (信立泰), China Resources Double-Crane Pharmaceutical (华润双鹤), Sichuan Kelun Pharmaceutical (科伦药业), Livzon Pharmaceutical Group (丽珠集团) and Humanwell Healthcare Group (人福医药). Jichuan Pharmaceutical (济川药业) is listed as an emerging player.
Does RHP have an API?
No public API is recorded for RHP.
What industry is RHP in?
RHP's product category is Pharmaceutical Manufacturing. Its primary akta.pro industry code is HLAGAHAL, GMP Scale-Up, Tech Transfer & Process Validation (PPQ), with a secondary code of HLAGAHAM, Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC). Its NAICS code is 325412 and its SIC code is 2834.